Advaxis Appoints Molly Henderson as Chief Financial Officer
June 06 2018 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology
company focused on the discovery, development and commercialization
of immunotherapy products, today announced the appointment of Molly
Henderson as Executive Vice President and Chief Financial Officer,
effective June 6, 2018.
Ms. Henderson joins Advaxis from Cedar Cliff, LLC, where she
served as a financial and business consultant to high-growth
entrepreneurial companies. Previously she was Chief Financial
Officer at Iovance Biotherapeutics, Inc. (formerly Lion
Biotechnologies, Inc.) (Nasdaq: IOVA), an immuno-oncology company
where she was responsible for all financial, SEC reporting, legal,
governance, human resources and IT-related functions, and raised
$100 million in equity capital. In her over twenty years of
financial experience, Ms. Henderson brings to Advaxis a
demonstrated set of skills that includes operational efficiency,
fund raising, M&A evaluation, investor relations, accounting
and financial controls.
“We welcome Molly to the Advaxis team and look forward to her
contributions,” said Ken Berlin, President and Chief Executive
Officer. “Molly has significant experience as a public company CFO
in the healthcare industry, including immuno-oncology, and in
managing the capital efficiency and financial requirements of a
development-stage biotechnology company like Advaxis. We are very
pleased to add Molly to our executive management team.”
Commenting on her appointment, Ms. Henderson said, “I have spent
the majority of my professional career supporting the development
of exciting growth companies in the healthcare industry, including
managing the finance function, raising capital and creating an
infrastructure for success. In particular, given my recent
experience in cancer immunotherapy, I am excited to be joining
Advaxis and to support its promising Lm platform technology.”
Prior to Iovance, for more than a decade Ms. Henderson was Chief
Business & Financial Officer, Senior Vice President of
VirtualScopics, Inc. (formerly Nasdaq: VSCP) during a period when
the company evolved from an early stage company to a
publicly-traded profitable business serving the biotechnology and
pharmaceutical industries. Earlier in her career Ms. Henderson was
Corporate Controller at Ultralife Corporation and an expert advisor
to entrepreneurs in Switzerland. She began her career as an audit
manager at PricewaterhouseCoopers.
Ms. Henderson holds an MBA and a BS in Accounting from the
University at Buffalo. She is a licensed CPA (inactive) in the
State of New York.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of proprietary
Lm-based antigen delivery products. These immunotherapies are based
on a platform technology that utilizes live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion
proteins. These Lm-based strains are believed to be a significant
advancement in immunotherapy as they integrate multiple functions
into a single immunotherapy and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T cell immunity,
activate the immune system with the equivalent of multiple
adjuvants, and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, neoantigen therapy, hotspot/
cancer antigens and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2017, and on Form 10-Q for the quarter ended January
31, 2018, which are available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180606005181/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorAdvaxis, Inc.Ranya Dajani,
609-250-7559Vice President, Business
DevelopmentDajani@advaxis.comorInvestors:LHA Investor
RelationsMiriam Weber Miller, 212-838-3777Mmiller@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024